Novartis, Merck Back Off on Prices, Rubius Leads IPO Charge, CRISPR Stocks Rattled

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Sage’s Depression Triumph, Biogen’s Alzheimer’s Defeat, & Apple Watch Hype
Sharpless in the Saddle, NIH Threatened Again, & PBMs Prep for Senate Scrutiny
Gottlieb Exits, Biogen’s Big Gene Therapy Buy, and Lilly’s Pre-Emptive Price Cut
Pharma Dodges Senate Bullet, Roche Pays $4.8B for Spark, & BMS-Celgene Deal Wobbles